Introduction
Lymphomas are malignant hematologic tumors associated with malignancy of
certain immune cells produced by proliferation and differentiation of
lymphocytes, and are classified into two categories according to
histopathologic changes: non-Hodgkin’s lymphoma (NHL) and Hodgkin’s
lymphoma (HL). They can be divided into B-cell, T-cell and NK-cell
lymphomas, in accordance to the origin of the lymphocytes. 2016 World
Health Organization (WHO) reclassify of hematopoietic and lymphoid
tissue tumors 1, lymphomas are mostly B-cell in
origin. Malignant lymphoma is becoming more frequent in China, which is
comparable to leukemia, and present remedy alternatives have no longer
improved outcomes.
There is presently no therapy for B cell lymphoma; it can only be slowed
or controlled. The stunning effects of gene editing in duchenne muscular
dystrophy (DMD)2 and sickle cellphone anemia
(SCD)3 have researchers interested. Jeffrey C Miller
et al 4 developed zinc finger nucleases (ZFNs) to
target genes, and with the rapid development of science and technology,
transcription activator-like effector nucleases (TALENs)5,6 and clustered regularly interspaced short
palindromic repeats (CRISPR) Cas9 7,8 have emerged one
after another, with CRISPR/Cas9 being the most thoroughly studied and
most commonly used.